Navigation Links
Biopharmaceutical Companies Transform Clinical Trial Strategies for Success in Global Marketplace
Date:4/13/2013

CHAPEL HILL, N.C., April 13, 2013 /PRNewswire/ -- Pharmaceutical companies in North America and Europe have recently been faced with two major concerns: clinical costs are continuing to rise and sales are either rising a little or not at all. In emerging markets, organizations are experiencing lower clinical costs and rapidly rising sales. Although mature markets still represent a majority of sales, it is clear that emerging markets offer significant cost savings and important future sales.

While there are many advantages that come along with expanding into these emerging markets, large countries like China and India are now requiring local clinical trials to win regulatory approvals to market products in those countries. Despite these obstacles, pharmaceutical organizations must evaluate the necessity of expanding their clinical programs into emerging markets in order to cut costs and boost sales.

In order to help biopharma organizations set a strategic direction for conducting clinical trial activities in emerging regions of the world, Best Practices, LLC conducted a primary research report. The report, Clinical Affairs Excellence: Benchmarking Clinical Trial Strategies for Pharmaceutical Success in a Global Marketplace, analyzes factors associated with outsourcing clinical trial activities – including cost, staffing, and quality – to help leadership evaluate the organization's approach to outsourcing relative to other market leaders.

Key study topics include:

  • Pharmaceutical presence in emerging markets
  • Evaluating resource levels
  • Outsourcing for key clinical trials
  • Benefits of clinical outsourcing

These research findings provide industry metrics and insights that can serve as a reference point for clinical leaders when formulating a strategic approach for engaging emerging regions in clinical affairs activities. The performance benchmark and field research harvested scores of insights and observations from seven clinical leaders at six pharmaceutical companies.

To review highlights of the full report, download a complimentary summary containing selected metrics and key findings, visit http://www.best-in-class.com/rr1212.htm.

For more information on this study or other recent primary research studies, contact us at 919.403.0251 or at bestpractices@best-in-class.com.

ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations. Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
4. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
7. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
8. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
10. Biopharmaceutical Service Providers Announce Collaborative Opening of Boston, MA Office
11. The Thousand-Year Business Model for a Modern Biopharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations ... Latin America . ... ... ... ...
(Date:6/23/2016)... The vast majority of dialysis patients currently ... are usually 3 times a week, with treatment times ... time, equipment preparation and wait time.  This regimen can ... patients who are elderly and frail.  Many elderly dialysis ... centers for some duration of time. Residents ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):